Augtyro for NTRK gene fusion-positive solid tumors
Quick answer: Augtyro is used for NTRK gene fusion-positive solid tumors as part of a ros1/ntrk tyrosine kinase inhibitor treatment regimen. Repotrectinib selectively inhibits ROS1 and TRKA/B/C kinases including resistance mutations The specific dosing for NTRK gene fusion-positive solid tumors is determined by your prescriber based on individual factors.
Why is Augtyro used for NTRK gene fusion-positive solid tumors?
Augtyro belongs to the ROS1/NTRK tyrosine kinase inhibitor class. Repotrectinib selectively inhibits ROS1 and TRKA/B/C kinases including resistance mutations This action makes it useful for treating or managing NTRK gene fusion-positive solid tumors in patients for whom this approach is clinically appropriate.
It is one of several treatment options. Whether Augtyro is the right choice for a specific patient depends on the type and severity of NTRK gene fusion-positive solid tumors, response to previous treatments, individual risk factors, and clinical guidelines.
Typical dosing for NTRK gene fusion-positive solid tumors
Common adult dosing range: 160 mg once daily for 14 days then 160 mg twice daily. The actual dose for NTRK gene fusion-positive solid tumors depends on:
- Severity of the condition
- Patient's age, weight, and organ function
- Other medications being taken
- Treatment response and tolerability
For complete dosing details, see the Augtyro medicine page.
What to expect
Augtyro treatment for NTRK gene fusion-positive solid tumors typically involves:
- Onset of effect: varies by indication and dose — some effects are immediate, others take days to weeks
- Treatment duration: some courses are short-term, others are long-term or lifelong depending on NTRK gene fusion-positive solid tumors
- Monitoring: follow-up visits to assess response and adjust dosing
- Side-effect awareness: learning what to expect and what warrants medical attention
Alternatives to consider
If Augtyro is not appropriate or not tolerated, alternatives within the same class or different therapeutic classes may be considered. See all ROS1/NTRK tyrosine kinase inhibitor for related options.
When to talk to your doctor
Discuss with your prescriber if you experience:
- Inadequate symptom control on Augtyro
- Side effects affecting daily life
- New medications or supplements that may interact
- Pregnancy planning or pregnancy
- Major changes in health status
Related information
Augtyro full prescribing information · All ROS1/NTRK tyrosine kinase inhibitor alternatives
Frequently asked questions
How effective is Augtyro for NTRK gene fusion-positive solid tumors?
Effectiveness varies by individual response, dose, and severity. Augtyro is one of several treatment options for NTRK gene fusion-positive solid tumors, supported by clinical evidence within the ros1/ntrk tyrosine kinase inhibitor class. Discuss expected response with your prescriber.
How long do I need to take Augtyro for NTRK gene fusion-positive solid tumors?
Treatment duration depends on the nature of NTRK gene fusion-positive solid tumors — some treatments are short-term, others long-term or lifelong. Never stop on your own; discontinuation requires clinical guidance to avoid relapse or rebound effects.
What are the main side effects of Augtyro when used for NTRK gene fusion-positive solid tumors?
Common and serious side effects are class-related and substance-specific. See the full medicine page for the complete profile. Report any unexpected effects to your prescriber.
Are there alternatives to Augtyro for NTRK gene fusion-positive solid tumors?
Yes. Multiple medicines and non-drug options exist for NTRK gene fusion-positive solid tumors. Alternatives within the ros1/ntrk tyrosine kinase inhibitor class share mechanisms; other classes may offer different approaches. Discuss with your clinician.
Last reviewed: by iMedic Medical Editorial Team. Our editorial process.